| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 57.738 | 199.130 | 901.149 | 1.537.824 | 2.654.769 | 3.858.635 |
| Total Income - EUR | - | - | - | 24 | 59.010 | 200.956 | 903.246 | 1.539.367 | 2.657.865 | 3.863.209 |
| Total Expenses - EUR | - | - | - | 2.008 | 56.562 | 191.783 | 844.610 | 1.426.505 | 2.533.434 | 3.593.556 |
| Gross Profit/Loss - EUR | - | - | - | -1.984 | 2.448 | 9.173 | 58.636 | 112.862 | 124.431 | 269.653 |
| Net Profit/Loss - EUR | - | - | - | -1.984 | 1.871 | 7.315 | 52.508 | 75.560 | 58.407 | 208.759 |
| Employees | - | - | - | 0 | 1 | 2 | 15 | 18 | 28 | 30 |
Check the financial reports for the company - Swixx Biopharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 1.274 | 2.058 | 24.047 | 52.368 | 165.226 | 213.283 |
| Current Assets | - | - | - | 8.026 | 20.841 | 37.439 | 156.675 | 335.417 | 910.889 | 957.385 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 277.420 | 158.118 |
| Receivables | - | - | - | 0 | 9.395 | 23.957 | 124.382 | 98.287 | 263.686 | 382.843 |
| Cash | - | - | - | 8.026 | 11.446 | 13.482 | 32.293 | 237.130 | 369.783 | 416.424 |
| Shareholders Funds | - | - | - | -1.941 | -33 | 7.282 | 59.628 | 135.373 | 193.369 | 401.047 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 10.677 | 22.864 | 32.930 | 132.655 | 265.500 | 901.287 | 770.266 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 5.167 | 5.276 | 3.389 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Swixx Biopharma S.r.l.